✦ LIBER ✦

A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy

✍ Scribed by Nancy B. Davis; Christopher W. Ryan; Walter M. Stadler; Nicholas J. Vogelzang

Book ID: 109052032
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 94 KB
Volume: 96
Category: Article
ISSN: 1464-4096
DOI: 10.1111/j.1464-410x.2005.05765.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized phase II study of atrasentan

Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer

✍ M. Dror Michaelson; Donald S. Kaufman; Philip Kantoff; William K. Oh; Matthew R. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 2 views

## Abstract ## BACKGROUND. Metastatic prostate cancer is characterized by the presence of osteoblastic bone metastases. Bone metastases account for most of the morbidity from this disease. Inhibition of osteoclast activity with the potent bisphosphonate zoledronic acid reduces skeletal complicatio

Can dutasteride delay or prevent the pro

Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study

✍ Fritz H. Schröder; Chris H. Bangma; Johannes M. Wolff; Antonio Alcaraz; Francesc 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB

Exploratory analysis on the effect of ra

Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues

✍ McLeod, David G.; Schellhammer, Paul F.; Vogelzang, Nicholas J.; Soloway, Mark S 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

## BACKGROUND. Black race has been associated with a significantly increased risk of prostate cancer mortality. This exploratory analysis investigated the effect of race on the clinical outcome of combined androgen blockade (CAB). METHODS. Data for analysis were obtained from a double-blind, rando

A phase II trial of imatinib mesylate in

A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy

✍ Amy M. Lin; Brian I. Rini; Vivian Weinberg; Kristen Fong; Charles J. Ryan; Jonat 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB

Locally advanced prostate cancer: Bioche

Locally advanced prostate cancer: Biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy

✍ Bernardo Rocco; Epifanio Scardino; Ottavio de Cobelli 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 40 KB 👁 2 views

I n the article by Bruchovsky et al., 1 intermittent androgen sup- pression was evaluated in patients with clinically locally advanced prostate cancer who developed biochemical disease recurrence after radiotherapy. We consider it to be of utmost important to improve currently existing knowledge re

Locally advanced prostate cancer—biochem

Locally advanced prostate cancer—biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy

✍ Nicholas Bruchovsky; Laurence Klotz; Juanita Crook; S. Larry Goldenberg 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 2 views